Introduction
Human immunodeficiency virus (HIV)-1-associated dementia (HAD) is a late-stage complication of advanced HIV-1 disease (Carpenter et al, 2000; Krebs et al, 2000; McArthur et al, 1999) . Clinically, HAD results in a spectrum of neurological and psychiatric symptoms, including cognitive impairment, hallucinations, delirium, coma, and ultimately death (Gelbard and Epstein, 1995; Janssen et al, 1991; Marder et al, 1996; Masliah, 1996; Navia et al, 1986) .
The histopathological correlate of HAD is HIV-1 encephalitis (HIVE), which occurs in most, but not all, cases of dementia related to HIV-1 infection (Glass et al, 1995; Masliah, 1996; Wiley, 1995) . HIVE features blood-brain-barrier (BBB) damage, productive viral infection, immune activation of mononuclear phagocytes (MP; brain macrophage and microglia), astrogliosis, and neuronal injury, apoptosis, and loss (Asare et al, 1996; Dickson et al, 1994; Gabuzda and Wang, 1999; Gendelman et al, 1997; Glass et al, 1995; Masliah et al, 2000; McArthur et al, 1999; Nath and Geiger, 1998; Navia et al, 1986; Rappaport et al, 1999; Wiley and Achim, 1994) . It is believed that MP, the predominate cell type infected in the brain, induce neuronal injury and death through the production of neurotoxins Genis et al, 1992; Giulian et al, 1990; Koenig et al, 1986; Ma et al, 1994; Moses et al, 1993; Nath et al, 1995; Pulliam et al, 1991; Ranki et al, 1995; Tornatore et al, 1991; Wiley et al, 1991) . Given what is known about the involvement of MP in HIVE, it is important to understand how MP become immune activated. Recently, it has been proposed that neurons may directly participate in the disease process by inducing MP R Cotter et al recruitment and activation through release of soluble chemotactic factors. This review will examine the role that neuronal chemokines play in MP recruitment and activation during HAD.
Chemokines and chemokine receptors in the CNS
Chemoattractant cytokines (chemokines) are soluble molecules that regulate the migration and activation of leukocytes into brain and other tissues (Kutsch et al, 2000; Wu et al, 2000) . More than 46 chemokines have been identified (Baggiolini et al, 1997; Zlotnik and Yoshie, 2000) and are classified into the following four groups (Table 1) : alpha (CXC), beta (CC), gamma (C-chemokines), and delta (CX3C), based on the arrangement of cysteine residues within the receptor-binding domain. For example, CXC chemokines have two cysteine residues separated by a single amino acid, whereas in CC chemokines the cysteines are adjacent. Chemokines exert their effects by binding to and activating a family of seven-transmembrane, G-protein-coupled receptors (GPCRs). These receptors are divided into four groups: κ -chemokine receptors (CXCR1-6), κ -chemokine receptors (CCR1-10), κ -chemokine receptors (XCR1), and κ-chemokine receptors (CX3CR1) (Hesselgesser and Horuk, 1999; Klein et al, 1999; van der Meer et al, 2000) (review in Gabuzda et al, 2002; Karpus, 2001; Miller and Meucci, 1999; Ransohoff, 1998) . In addition to mediating leukocyte recruitment and activation, chemokine receptors, such as CCR5 and CXCR4, also serve as coreceptors for HIV-1 (Dragic et al, 1996; . Importantly, the endogenous ligands (RANTES, macrophage inflammatory protein [MIP]-1κ /κ ) for these receptors have been shown to block HIV-1 binding and entry, suggesting that the production of these factors may be an important defense mechanism against HIV-1 infection in the human host (Kornbluth et al, 1998) .
A wide range of chemokines are expressed in the brain during diseases, including κ -chemokines, such as interleukin-8 (IL-8, CXCL8) and stromal-derived factor-1 alpha (SDF-1κ , CXCL12); κ -chemokines, such as monocyte chemoattractant protein (MCP)-1 (CCL2), MIP-1κ (CCL3), MIP-1κ (CCL4), and RANTES (CCL5); and the κ-chemokine, fractalkine (FKN, CX3CL1) (Conant et al, 1998; Cotter et al, 1999b; Coughlan et al, 2000; Desbaillets et al, 1994; Gabuzda and Wang, 2000; Kornbluth et al, 1998; Persidsky, 1999; Zheng et al, 1999) . Chemokines, such as SDF-1κ , IL-8, and fractalkine (FKN), are constitutively produced in the brain and play an important role in central nervous system (CNS) homeostasis and development (Coughlan et al, 2000; Gabuzda and Wang, 2000; Gleichmann et al, 2000; Harrison et al, 1998; Horuk et al, 1996; Meucci et al, 1998 Meucci et al, , 2000 Nagasawa et al, 1996) . Upon binding to neu- CXCR2  CXCL4  PF4  Unknown  CXCL5  ENA-78  CXCR2  CXCL6  GCP-2  CXCR1, CXCR2  CXCL7  NAP-2  CXCR2  CXCL8 IL
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ronal receptors (CXCR4, CXCR2, and CX3CR1), these chemokines activate signaling pathways that regulate neuronal survival, injury, and repair (Kaul and Lipton, 1999; Meucci et al, 1998 Meucci et al, , 2000 Peng et al, 2002; Tong et al, 2000; Zheng et al, 2001) . For example, knockout mice lacking CXCR4 exhibit abnormal migration of cerebellar external granule layer cells and other nervous system defects (Zou et al, 1998) . These findings underscore the importance of chemokines and their receptors in neuronal cell development and maintenance.
Fractalkine and brain inflammation in HIV-1-associated dementia R Cotter et al 587 Chemokines also play a critical role in the host response to CNS injury and infection. Indeed, the role of chemokines and their receptors in neurodegenerative disorders, such as multiple sclerosis, Alzheimer's disease, stroke, and HAD, has been extensively investigated and reviewed (Gabuzda et al, , 2002 Karpus, 2001; Letendre et al, 1999; Minami and Satoh, 2000; Ransohoff, 1997; Sanders et al, 1998) . Several reports have shown that SDF-1κ , IL-8, MIP-1κ , MIP-1κ , RANTES, MCP-1, and FKN are up-regulated in brain tissue and cerebrospinal fluid (CSF) from HAD patients (Coughlan et al, 2000; Kelder et al, 1998; Persidsky et al, 1999; Tong et al, 2000; Zheng et al, 1999 Zheng et al, , 2000 . It has been proposed that these chemokines contribute to HAD pathogenesis through recruitment of monocytes into the brain, through initiation of neuroinflammatory cascades that affect viral replication, through induction of neural signaling and apoptosis, or through initiation of neuronal protection and repair (Albright et al, 1999; Broder and Collman, 1997; Cotter et al, 2001; Endres et al, 1996; Ghorpade et al, 1998; Kitai et al, 2000; Lavi et al, 1997; Luster, 1998; Mackay, 1996; Shieh et al, 1998; Vallat et al, 1998; Vicenzi et al, 2000; Zheng et al, 1999 ) (review in Gabuzda et al, 2002; Miller and Meucci, 1999) . Although it is evident that chemokines are an important component of the host immune response, the nature of their role in disease pathogenesis is only beginning to be understood.
Neuronal chemokines and MP activation, a "chicken or egg" question
Traditionally, it was believed that MP activation and chemokine production preceded neuronal injury in HIVE. However, new evidence suggests that neurons themselves may initiate MP recruitment and activation (Biber et al, 2001; Harrison et al, 1998) . Indeed, it has been proposed that in response to injury, neurons produce chemokines, such as FKN (Harrison et al, 1998) , that act as "distress signals." Upon release, these factors recruit MP to sites of injury and stimulate the production of inflammatory factors with the potential to repair or exacerbate neuronal damage (Tong et al, 2000; Zheng et al, 2000) (Figure 1 ).
There are several lines of evidence that provide support for this hypothesis. First, excitotoxinmediated neuronal injury, as well as nerve axotomy, induces production of the neuronal chemokine FKN (Chapman et al, 2000a; Harrison et al, 1998; Zheng et al, 2000) . Second, this neuronal chemokine is also up-regulated in HAD brain tissue (Pereira et al, 2001; Tong et al, 2000; Zheng et al, 2000) and released in response to neuronal apoptosis induced by HIV-1 progeny virions (IIIB and ADA) and gp120 (Zheng et al, 2000) . Third, both the soluble and membranebound forms of FKN have been shown to attract and immobilize leukocytes, such as monocytes and lymphocytes (Boehme et al, 2000; Chapman et al, 2000a Chapman et al, , 2000b Combadiere et al, 1998; Dorf et al, 2000; Fong et al, 1998; Goda et al, 2000; Harrison et al, 1998; Imai et al, 1997; Tong et al, 2000) . The monocytes, when recruited to the site of injury, could secrete other chemokines that recruit additional leukocytes to the site of tissue injury and induce inflammation. Indeed, the FKN-CX3CR1 pair may participate in the generation and progression of inflammatory disorders within the brain and periphery. FKN has already been shown to play a role in a variety of pathological conditions related to inflammation, including atherosclerosis (Alexander, 2001; Greaves and Gordon, 2001; McDermott et al, 2001) , renal inflammation (Cockwell et al, 2002; Feng et al, 1999; Furuichi et al, 2001) , airway inflammation , psoriasis (Raychaudhuri et al, 2001) , arthritis (Ruth et al, 2001; Volin et al, 2001) , cardiac allograft rejection , progression of acquired immunodeficiency syndrome (AIDS) (Faure et al, 2000; Foussat et al, 2001) , and CNS inflammation (Boehme et al, 2000; Harrison et al, 1998; Hughes et al, 2002; Maciejewski-Lenoir et al, 1999; Nishiyori et al, 1998; Schwaeble et al, 1998; Zujovic et al, 2000) . These observations suggest that FKN and its receptor have a unique role in regulation of the host response to disease (Fong et al, 1998; Harrison et al, 1998) .
The balance of data demonstrates overwhelming support for FKN mediated recruitment of leukocytes. However, studies with FKN and CX3CR1 knockout mice (Cook et al, 2001; Jung et al, 2000) have tempered the importance of FKN and CX3CR1 in leukocyte recruitment. In studies (Cook et al, 2001 ) with FKN-deficient mice, responses to a variety of inflammatory stimuli were indistinguishable from those of wild-type mice in an intestine inflammation model system (Cook et al, 2001) . In other reports (Jung et al, 2000) , the absence of CX3CR1 did not interfere with either monocyte extravasation or dendritic cell migration and differentiation in a peritonitis model. Further, CX3CR1-deficient microglia exhibited proficient responses to peripheral nerve injury, indicating unimpaired neuronal-glial cross-talk in the absence of CX3CR1 (Jung et al, 2000) . These findings suggest that other means of neuronal-glial linkage exist. Nevertheless, to elucidate the exact role of FKNand CX3CR1-expressing cells in disease pathogenesis, further studies are certainly required. Moreover, FKN-CX3CR1 interactions may mediate other inflammatory responses besides the recruitment of leukocytes. The following section will examine how FKN mediates communication between neurons and MP during homeostasis and disease.
FKN expression, structure, and regulation FKN (neurotactin, CX3CL1) is a 373-amino acid, multidomain molecule found in a wide variety of tissues, including liver, intestine, kidney, and brain.
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Figure 1
A proposed pathophysiological mechanism for how MP activation influences neuronal injury in HAD. During monocyte/macrophage maturation, macrophages acquire the ability to sustain productive HIV-1 infection. Release of progeny virion leads to infection of resident brain microglia. Uninfected or virus-infected MP can be immune-activated by a process that remains incompletely understood, but likely involves cytokines, chemokines, and cell-to-cell interactions. Released from injured neurons, the neuronal chemokine fractalkine (FKN) represents one pathway through which MP activation may occur. After recruiting MP to the site of injury, FKN may activate MP to produce neurotrophic/toxic factors that affect neuronal survival and induce CNS inflammation. In turn, recruited MP may also become infected and activation leading to the production of chemokines, cytokines, and glutamate. Chemokines, gp120, and whole virions may also interact with neuronal receptors to alter intracellular signal transduction pathways, leading to neuronal dysfunction and death.
Structural components of FKN include a 76-amino acid chemokine domain (CD) at the N-terminus, which is important in the binding, adhesion, and activation of its target cells (Harrison et al, 2001; Mizoue et al, 1999 Mizoue et al, , 2001 Goda et al, 2000; Haskell et al, 2000) . In addition, FKN has a 241-amino acid mucin-like stalk, which extends the chemokine domain away from the cell surface in order to aid in the adherence of CX3CR1-expressing cells (Fong et al, 2000) . FKN also has an 18-amino acid stretch of hydrophobic residues that spans the cell membrane, and an extended C-terminus that anchors it to the cell surface (Cook et al, 2001; Hoover et al, 2000; Lucas et al, 2001) . These unique structural features enable FKN to mediate chemotaxis, adherence, and activation of CX3CR1-expressing cells.
FKN is novel in that it is the only chemokine known to be expressed at higher levels within the CNS than in the periphery (Bazan et al, 1997) . In the CNS, FKN is constitutively expressed by neurons (Harrison et al, 1998; Hughes et al, 2002) (Figure 2 ) and can be induced by astrocytes (Hughes et al, 2002; Pereira et al, 2001; Zheng et al, 2002) . It is upregulated and released in response to proinflammatory stimuli, such as lipopolysaccharide (LPS), IL-1κ , tumor necrosis factor (TNF)-κ , CD40L, and interferon (IFN)-κ (Fraticelli et al, 2001; Fujimoto et al, 2001; Garcia et al, 2000; Hughes et al, 2002; Imaizumi et al, 2000; Pereira et al, 2001; Yoshida et al, 2001; Zheng et al, 2002) . This up-regulation is believed to occur through activation of nuclear factor (NF)-κB (Garcia et al, 2000) .
FKN is also distinct from other chemokines, because it exists in both membrane-bound and soluble isoforms (Fong et al, 2000; Harrison et al, 2001; Mizoue et al, 2001) . In response to excitotoxic stimuli, the membrane-spanning domain is rapidly cleaved and a soluble form of FKN is released from the neuronal cell surface (Chapman et al, 2000a; Zheng et al, 2000) . Proteolytic cleavage of FKN is proposed to occur at a di-arginine sequence located next to the transmembrane domain (Bazan et al, 1997; Cook et al, 2001; Fong et al, 2000; Harrison et al, 1998 Harrison et al, , 2001 ). However, the exact location of the cleavage site remains to be confirmed (Tsou et al, 2001) . FKN cleavage can be mediated by two distinct metalloproteinase-dependent activities: a constitutive FKN sheddase, which is active under normal cell culture conditions, and an inducible FKN sheddase that can be rapidly activated by phorbol esters, such as phorbol 12-myristate 13-acetate (PMA) (Garton et al, 2001; Tsou et al, 2001) . Recently, inducible cleavage has been shown to be mediated by the TNF-κ -converting enzyme (TACE), which belongs to a family of proteins containing a metalloprotease domain (Garton et al, 2001; Tsou et al, 2001) .
The receptor for FKN, CX3CR1 (Combadiere et al, 1998) , is expressed on monocytes (Cambien et al, 2001; Chapman et al, 2000b) , dendritic cells (Dichmann et al, 2001) , T lymphocytes (Fong et al, 1998; Foussat et al, 2000; Fraticelli et al, 2001) , natural killer cells (Fong et al, 1998; Imai et al, 1997; Inngjerdingen et al, 2001) , astrocytes (Dorf et al, 2000) , neurons (Hughes et al, 2002; Meucci et al, 2000; Tong et al, 2000) , and brain microglia (Boehme et al, 2000; Chapman et al, 2000a; Harrison et al, 1998; Hughes et al, 2002) . Like other chemokine receptors, CX3CR1 (previously called V28) belongs to a family of GPCRs, which feature a seventransmembrane domain, an extracellular N-terminus, and a cytoplasmic C-terminus. GPCRs interact with and signal through heterotrimeric guanine nucleotide-binding regulatory proteins (G-proteins).
Upon stimulation by a ligand, GPCRs undergo a conformational change that leads to activation of the G-protein by GDP-GTP exchange, followed by uncoupling of the G-protein from the receptor. Upon activation, G-proteins trigger a cascade of signaling events that regulate various cellular functions (Devi, 2000) .
FKN functions: Cell adhesion and neuroprotection
In the brain, FKN is believed to regulate a complex network of paracrine and autocrine interactions between neurons and surrounding MP (Boehme et al, 2000; Harrison et al, 1998; Maciejewski-Lenoir et al, 1999) , primarily through chemoattraction and adhesion. Both the soluble and membrane-bound forms of FKN are potent inducers of chemotaxis (Harrison et al, 2001) . However, it is the membrane-bound form that enables FKN to immobilize CX3CR1-expressing cells, such as leukocytes (Boehme et al, 2000; Chapman et al, 2000a Chapman et al, , 2000b Combadiere et al, 1998; Dorf et al, 2000; Fong et al, 1998; Harrison et al, 1998; Imai et al, 1997; Tong et al, 2000) . Mutation analyses and knockout mouse experiments have shown that specific residues within the FKN CD, such as Lys-7 and Arg-47, are important determinants in mediating binding, signaling, and adhesion of CX3CR1-expressing cells (Goda et al, 2000; Harrison et al, 2001; Haskell et al, 2000; Mizoue et al, 1999 Mizoue et al, , 2001 . Further, the adherence of FKN to CX3CR1-expressing leukocytes is believed to be integrin independent (Fong et al, 1998) . Other studies suggest that adhesion of CX3CR1-expressing leukocytes is independent of G-protein activation (Haskell et al, 1999) . It is R Cotter et al possible that the mucin-like domain of FKN may aid in adherence of CX3CR1-expression cells by extending the chemokine domain away from the cell surface in order to present it to trafficking leukocytes (Fong et al, 2000) . Additionally, it is possible that the ability of FKN to mediate adhesion of trafficking cells may be a function of its slow receptor off-rate (Haskell et al, 2000) . Nevertheless, it is clear that FKN and CX3CR1 fulfill important roles in leukocyte trafficking.
In addition to chemoattraction and adhesion, FKN may serve other functions, such as inhibition of HIV-1 infection and neuroprotection (Fong et al, 1998; Harrison et al, 1998; Haskell et al, 2000; Inngjerdingen et al, 2001; Tong et al, 2000) . For example, FKN inhibits HIV-1 entry into CX3CR1-expressing cells (Faure et al, 2000) and inhibits neuronal injury induced by gp120 (Meucci et al, 2000) , platelet-activating factor (PAF), and the regulatory HIV-1 gene product, Tat (Tong et al, 2000) . FKN has also been shown to inhibit Fas-mediated death in microglia (Boehme et al, 2000) . The protective functions of FKN are believed to be mediated through activation of signaling pathways involving the protein kinase, Akt (protein kinase B), and NF-κB, which are major components of prosurvival signaling pathways in neurons and microglia (Boehme et al, 2000; Meucci et al, 2000) .
FKN and macrophage activation: Dysregulation of neurotrophic/toxic factors?
Because CX3CR1 is highly expressed on MP, it is possible that FKN-CX3CR1 interactions play an important role in mediating MP immune activation. Upon binding to CX3CR1, FKN has been shown to stimulate TNF-κ and IL-8 production in MP (Figure 3) Zujovic et al, 2000) . Although many of the individual factors secreted by FKN-activated MP remain to be determined, it is known that HIV-1-infected and immune-activated MP are capable of producing a wide variety of toxic factors. These factors include proinflammatory cytokines such as TNF-κ , IL-1κ (Sebire et al, 1993) , glutamate (Jiang et al, 2001) , arachidonic acid and its metabolites (Genis et al, 1992) , PAF (Gelbard et al, 1994) , quinolinic acid (Heyes et al, 1991; Kerr et al, 1998) , NTox (Giulian et al, 1996) , nitric oxide (NO) (Adamson et al, 1996) , and reactive oxygen species (ROS) (Mollace et al, 2001) . Alternatively, viral infection and FKN-mediated activation of MP may regulate production of trophic factors that mediate neuronal growth and repair . A number of neurotrophic factors are secreted by MP (Barnea et al, 1996; Elkabes et al, 1996) , including brainderived neurotrophic factor (BDNF) (Kerschensteiner et al, 1999; Miwa et al, 1997) , κ -nerve growth factor (κ NGF) (Caroleo et al, 2001; Garaci et al, 1999; Lopez et al, 2001) , transforming growth factor-beta (TGF-κ ) (Chao et al, 1995) , neurotrophin-3 (NT3) (Kullander et al, 1997; Loy et al, 1994; Mallat et al, 1989; Rocamora et al, 1996; Saad et al, 1991) , and glialderived neurotrophic factor (GDNF) (Batchelor et al, 1999) . Withdrawal or dysregulation of these factors can result in neuronal injury and death (Deshmukh et al, 1996) . Through enhanced neurotoxin secretion and dysregulated neurotrophin production, HIV-1-infected and FKN-activated MP may induce neuronal injury and death in HIVE (Aquaro et al, 2000; Conant et al, 1998; Cotter et al, 1999a; Fischer-Smith et al, 2001; Gabuzda et al, 1998; Gendelman, 1997; Glass et al, 1995; Koenig et al, 1986; Lopez et al, 2001; Nath and Geiger, 1998; Perno et al, 1997; Strizki et al, 1996; Wiley et al, 1986; Zheng and Gendelman, 1997) .
FKN-induced secretory factor production is believed to occur through activation of intracellular signaling pathways (Cambien et al, 2001; Zheng et al, 2002) . Therefore, the following section will discuss the relevant intracellular signaling pathways resulting from FKN-mediated activation of CX3CR1 expressing-MP.
FKN-mediated signal transduction pathways
Binding of FKN to CX3CR1 on MP initiates multiple signal transduction pathways and leads to the activation of a wide variety of protein kinases, including the tyrosine kinases (the Src tyrosine kinase family and Syk tyrosine kinase family), calcium calmodulin kinase (CaMK), protein kinase C (PKC), phosphatidylinositide 3-kinase (PI 3-kinase), protein kinase B, mitogen-activated protein kinases (MAP kinases), and NF-κB (Cambien et al, 2001; Garcia et al, 2000) . Activation of these signal transduction pathways leads to elevation of cytosolic free calcium and modifications in enzymes, ion channels, transcriptional activators, and transcriptional regulators (Cambien et al, 2001; Iismaa et al, 1995) .
Several studies have shown that binding of FKN to CX3CR1 induces the activation of MAP kinases (Figure 4) (Cambien et al, 2001; Zheng et al, 2002) . Activation of MAP kinase pathways stimulate Figure 4 Overview of proposed MAP kinase and protein kinases B and C signal transduction events in mononuclear phagocyte (MP)-mediated production of proinflammatory factors or neurotrophic/toxic factors. FKN can bind the chemokine receptor CX3CR1 on MP and activate MAP kinase signaling through the κ or κ κ subunit of G-protein, which can further activate one or more types of MAP kinases. These MAP kinases include extracellular signal-related kinases (ERK1 and ERK2) and stress-activated protein kinases (SAPK1/JNK1 and SAPK2/p38). In addition, FKN can also activate intracellular signaling pathways, such as increasing cytosolic free calcium, activation of phosphatidyl inositol 3-kinase (PI-3K) and protein kinase B (PKB), and alteration of protein kinase C, which further activate MP. This activation causes the production of proinflammatory factors or multiple neurotrophic/toxic factors. The inhibitors for different kinase pathways can be used as tools to elucidate the signaling pathways involved in MP activation events. Some of the stimulation pathways may increase the cellular activation state and cause overproduction of cytokines or neurotoxins, which mediate MP-induced neuronal injury in HAD. R Cotter et al cell growth and differentiation by regulating gene translation and expression (Lopez-Ilasaca, 1998; Lopez-Illasaca et al, 1997) . There are three distinct MAP kinase cascades (Figure 4 ): c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), p38 (Lopez-Ilasaca, 1998) , and extracellular signalrelated kinases (ERK1/ERK2). The JNK/SAPK pathway is induced by exposure to ultraviolet radiation, heat shock, or inflammatory cytokines. The p38 pathway is activated in response to inflammatory cytokines, endotoxins, and osmotic stress. The ERK pathway is stimulated following binding of extracellular growth factors (for example, epidermal growth factor, EGF) to tyrosine kinase-linked receptors. It appears that each of the three MAP kinase pathways, ERK1/2, p38, and JNK, are activated during the binding of FKN to CX3CR1 on monocytederived macrophages (MDM) . Interestingly, production of MIP-1κ and IL-8 by FKNactivated MP can be blocked by MAP kinase inhibitors, such as PD98056 (ERK), SB203850 (p38), and SP600125 (JNK) . Activation of MAP kinase signaling appears to be critical for FKN-induced capture, adhesion, and activation of MP (Cambien et al, 2001; Kansra et al, 2001; Zheng et al, 2002) . Thus, multiple protein kinases appear to be involved in mediating the effects of FKN upon its target cells. The elucidation of specific pathways through which FKN induces MP activation and regulates production of neurotrophic/toxic factors will be critical to understanding disease pathogenesis in HAD and other neurodegenerative disorders.
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Summary
In summary, the evidence presented within this review suggests that the expression and production of neuronal chemokines, such as FKN, may be a compensatory or reparative response to injury in the brain. As such, we propose that in HAD, viral proteins, such as gp120, induce neuronal injury, leading to the up-regulation or release of FKN. Acting as a "distress signal," FKN may then recruit and activate CX3CR1-expressing MP to the site of injury (Fong et al, 2000; Harrison et al, 2001) . Dysregulation of this response may result in further neuronal injury as MP themselves become activated to produce neurotoxins. This, in turn, may induce a cycle of inflammation and injury. Identification of the pathways through which FKN induces MP activation could lead to the development of agents that impede or prevent further neuronal injury in HAD and other neurodegenerative disorders.
